reports
Radius Recycling Inc: 1 director
A director at Radius Recycling Inc sold 17,675 shares at 17.080USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Gurnet Point Capital and Patient Square Capital Complete Their Acquisi...
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc. CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”). Radius is a global, commercial-stage biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and neuro-orphan diseases. Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
VCYT VERACYTE INC
RDUS RADIUS HEALTH INC.
FOLD AMICUS THERAPEUTICS INC.
CYTK CYTOKINETICS INCORPORATED
AVXL ANAVEX LIFE SCIENCES
AGIO AGIOS PHARMACEUTICALS INC.
NTLA INTELLIA THERAPEUTICS INC.
CYRX CRYOPORT INC.
DH DELICE HOLDING
FNKO FUNKO CLASS A
RCKT ROCKET PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
ALEC ALECTOR
RAD RITE AID CORPORATION
TMDX TRANSMEDICS GROUP
CHWY CHEWY INC. CLASS A
HCAT HEALTH CATALYST
RAPT RAPT THERAPEUTICS
ALT ALTIMMUNE INC
AVEO AVEO PHARMACEUTICALS INC.
SPT SPROUT SOCIAL
FSTX F-STAR THERAPEUTICS INC
MASS 908 DEVICES
DAWN DAY ONE BIOPHARMACEUTICALS INC
GTLB GITLAB INC
AGL AGILON HEALTH INC
VERV VERVE THERAPEUTICS INC
GLUE MONTE ROSA THERAPEUTICS INC
BRZE BRAZE INC
RXRX RECURSION PHARMACEUTICALS INC
JANX JANUX THERAPEUTICS INC
WEBR WEBER INC
Radius Health Announces Agreement to be Acquired by Gurnet Point Capit...
Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital Transaction delivers immediate value and liquidity to Radius shareholdersResult of nine-month strategic review process by the Radius Board to maximize shareholder valuePotential per share value of $11.00, including $10.00 cash paid at closing and potential $1.00 CVRRepresents total transaction consideration of up to approximately $890 million BOSTON and CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced tha...
Menarini Group and Radius Health Submit New Drug Application to the U....
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patientsPriority Review requested; if accepted, anticipate an 8-month FDA reviewPositive EMERALD study data previously announced on October 20, 2021First, and currently only, investigational oral SERD with positive topline resultsAdditional data presented at SABCS (December 2021) and ASCO (June 2022)Plan to file marketing authorization application for elacestrant in the EU in 2H 2022 FLORENCE, Italy and BOSTON, June ...
Radius Health Expands Non-US Market Footprint for TYMLOS
Radius Health Expands Non-US Market Footprint for TYMLOS Globalization has been a key priority for the Company over the past two yearsThree additional market agreements now signed and executed:- Labatec Pharma SA: Switzerland, Middle East & North Africa (MENA) countries- Pharmbio Korea Inc.: South Korea- Biosidus: Colombia, South AmericaEconomics: upfront payments, regulatory & commercial milestones, and COGS marginAdds 13 new countries to the current non-US countries of Japan and CanadaJapan: regulatory approval of 14-day cartridge anticipated in 2H 2022 followed by launchCanada: regulator...
Menarini Group and Radius Health, Inc. present a subgroup analysis fro...
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) FLORENCE, Italy and BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health...
Radius Files Definitive Proxy and Mails Letter to Stockholders
Radius Files Definitive Proxy and Mails Letter to Stockholders Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE Proxy Card Details Company’s Significant Progress Since 2020, Under Refreshed Board and Management Team BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced that it has filed its definitive proxy statement with the Securities and Exchange Commission (“SEC”) for its upcomi...
Radius Health Update on Abaloparatide Transdermal System
Radius Health Update on Abaloparatide Transdermal System Company ascertained regulatory clarity for possible forward progression of abalo-TDSAdditional and successful clinical trial would be required to advance towards an NDA filingNew timeline for earliest possible abalo-TDS launch: 2H 2025Based on regulatory clarity, timeline, and costs, Radius will cease all work on the programEliminates prospective program costs: $100+ million over 3+ years: CMC, clinical, and launchCompany continues to dynamically manage capital and its allocation, risk, and overall timelines BOSTON, June 01, 2...
Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Li...
Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors Further Expands Board’s Expertise and Gender Diversity Enhances Corporate Governance BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced that it has added two new independent members to the Board of Directors (the “Board”). Effective immediately, Jennifer A. Jarrett and Susan Vissers Lisa have joined the Board as Class I and Class III directors, respectively. In addition, Radius’ Board also announced several corporate governan...
Menarini Group and Radius Health, Inc. announce publication of elacest...
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology EMERALD study met both its primary end points of progression-free survival (PFS) in overall population and in ESR1 mutated patientsPFS rate at 12 months with elacestrant was 22.3% vs. 9.4% with SOC in the overall population, and 26.8% vs. 8.2% in the ESR1 mutation populationData demonstrated elacestrant significantly reduced the risk of disease progression or death by 30% in all patients and by 45% in patients with ESR1 mutationCompared w...
Radius Health, Inc. First Quarter 2022 Results
Radius Health, Inc. First Quarter 2022 Results Q1 2022 TYMLOS® product net revenue of $43 million vs. $45 million in Q1 2021° Q1 results: in-line with previously guided 1H 2022 company target of $97 million° Reiterating FY 2022 TYMLOS Net Revenue guidance of $232 million° Seasonality, as previously announced: 42% of net revenue in 1H and 58% in 2H 2022° Patient Growth: average active patients on therapy increased by 4% compared to Q1 2021Productivity improvement continued: revenue per commercial headcount up 32% vs. Q1 2021TYMLOS for the Male indication: sNDA filed in Q1 2022 with launch pl...
Radius Health to Release First Quarter 2022 Financial Results, Host Co...
Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022 BOSTON, April 25, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that it will release its first quarter 2022 financial results on Thursday, May 5, 2022. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the results and provide a business update. Conference Call Information:Domestic Dial-In Number: 1 (866) 323-7965International Dial-In Number: 1 (346) 406-0961Conference...
Radius Provides Agenda for Today’s R&D Webcast
Radius Provides Agenda for Today’s R&D Webcast Focus: RAD011, an investigational synthetic cannabidiol oral solutionWebcast details: 10:00am to 12:00pm for current or prospective investors and sell side analystsObjectives: asset overview, science, regulatory, and clinical translation progress since acquisition BOSTON, April 05, 2022 (GLOBE NEWSWIRE) -- Today, Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) will host its Neuroscience R&D webcast to discuss RAD011, our investigational synthetic cannabidiol oral solution with potential utilization in multiple neuro-endocrine,...
Radius Health Announces Leadership Appointments
Radius Health Announces Leadership Appointments BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), today announced appointments to new roles on its executive leadership team, effective immediately. Mark Conley has joined Radius as the Company’s Chief Financial Officer. In addition, Kim Clarke has been promoted to the General Counsel position. Both will report to Kelly Martin, the Chief Executive Officer. Mark Conley is a Certified Public Accountant with over 30 years of experience in publicly listed companies. His experience in...
Radius Health Provides Business Update on Bone Health
Radius Health Provides Business Update on Bone Health Exclusive extension of research discovery collaboration with Mass General Hospital (MGH)Focus of the program: development of novel oral SIK inhibitors for musculoskeletal diseasesExtension of activity is based on data from existing collaboration which generated nonclinical molecule data demonstrating oral activity of the skeletal anabolicTYMLOS® IP: additional patent issued that extends patent protection to January 10, 2040 BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provid...
Wells Fargo Equity Research to Host Fireside Chat with Radius CEO
Wells Fargo Equity Research to Host Fireside Chat with Radius CEO BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that Kelly Martin, CEO, has accepted an invitation to participate in a virtual fireside chat hosted by Mohit Bansal, Managing Director of Equity Research at Wells Fargo. The event will take place on Friday, March 11, 2022 at 11:00am ET. A live webcast can be accessed on the investor relations section of the Company’s website, About RadiusRadius is a global biopharmaceutical company focused on address...
Radius to Host Neuroscience R&D Webcast April 5, 2022
Radius to Host Neuroscience R&D Webcast April 5, 2022 Focus: RAD011, our investigational synthetic cannabidiol oral solutionBroad market interest in the underlying science, data, and clinical translation of the assetGoal: provide foundational review of the asset and progress since acquisition in December, 2020 BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced details of its virtual R&D Webcast focused on RAD011. RAD011 is the Company’s investigational synthetic cannabidiol oral solution which has potential utili...
Radius Health Files sNDA for TYMLOS® in Men with Osteoporosis
Radius Health Files sNDA for TYMLOS® in Men with Osteoporosis Filed sNDA with the FDA ahead of schedule on Friday, February 25, 2022Filing based on the positive ATOM study data previously announced on October 18, 2021There is a 10-month FDA review BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided a business progress and regulatory update. On February 25, 2022, the Company filed a Supplemental New Drug Application (sNDA) with the Food and Drug Administration (FDA) for TYMLOS (abaloparatide) subcutaneous injection in men wit...
Radius Health, Inc. Fourth Quarter & Full Year 2021 Results
Radius Health, Inc. Fourth Quarter & Full Year 2021 Results Q4 2021 TYMLOS® net revenue of $65 million vs. $60 million in Q4 2020, up 9%This is a record quarter – over 18 quarters – since the launch in May 2017FY 2021 TYMLOS Net Revenue of $219 vs. $208 million in FY 2020, up 5%Net Loss reduced by ~36%: ($70) million FY 2021 vs ($109) million FY 2020Adjusted EBITDA (Non-GAAP) loss reduced by ~56%: ($24) million FY 2021 vs. ($54) million FY 2020FY 2022 financial objectives: $232 million TYMLOS Net RevenueIncorporate seasonality of Net Revenue: ~42% in 1H and ~58% in 2H 2022($5) to $5 mi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.